Sugi Predict

Sugi Predict / Compounds / SCHEMBL6952172

SCHEMBL6952172

SCHEMBL6952172

Oc1cc(O)n2nc(C3CC3)cc2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 1/20 0.40
▸ HPGD P15428 5/20 0.34
▸ GAA P10253 2/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ POLB P06746 2/20 0.33
▸ BLM P54132 1/20 0.33
▸ PLAT P00750 1/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ LMNA P02545 3/20 0.31
▸ MAPT P10636 2/20 0.31
▸ KDM4E B2RXH2 2/20 0.31
▸ PARP1 P09874 1/20 0.31
▸ NPC1 O15118 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ PKM P14618 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ HTT P42858 1/20 0.30
▸ MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5052666 0.83 MAPT (0.42) FYNHPGDGAAALDH1A1POLB
SCHEMBL18781131 0.77 MAPT (0.38) FYNHPGDGAAALDH1A1HSD17B10
SCHEMBL25257344 0.77 TYK2 (0.36) PLAT
SCHEMBL1396116 0.75 FYN (0.42) FYNALDH1A1POLBPLATKMT2A
SCHEMBL25223858 0.74 TSHR (0.36) HPGDGAAALDH1A1HSD17B10POLB
SCHEMBL25276711 0.74 TSHR (0.36) HPGDGAAALDH1A1HSD17B10POLB
SCHEMBL2441107 0.73 PDE10A (0.50) HPGDALDH1A1SMN1; SMN2MAPTKDM4E
SCHEMBL25214869 0.72 — —
SCHEMBL14211728 0.71 KDM4E (0.42) ALDH1A1POLBSMN1; SMN2KMT2AMAPT
SCHEMBL3338989 0.70 CXCR2 (0.47) FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586623-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-11-19 — — US disclosed
US-8518943-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-08-27 — — US disclosed
US-8518943-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-08-27 — — US disclosed
US-20120214815-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2012-08-23 — — US disclosed
US-20120214815-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2012-08-23 — — US disclosed
US-20120196866-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2012-08-02 — — US disclosed
US-20120196866-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2012-08-02 — — US disclosed
US-8183241-B2 2-oxo-1-pyrrolidine derivatives UCB PHARMA, S.A. (BE) 2012-05-22 — — US disclosed
US-8183241-B2 2-oxo-1-pyrrolidine derivatives UCB PHARMA, S.A. (BE) 2012-05-22 — — US disclosed
US-8178533-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2012-05-15 — — US disclosed
US-8178533-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2012-05-15 — — US disclosed
EP-2308870-A2 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses UCB Pharma S.A. (BE) 2011-04-13 — — EP disclosed
EP-2308867-A2 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses UCB Pharma S.A. (BE) 2011-04-13 — — EP disclosed
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2009-12-17 — — US disclosed
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2009-12-17 — — US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 — — US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214815-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 FYN 1970/4885HPGD 172/4885GAA 138/4885
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 FYN 1970/4885HPGD 172/4885GAA 138/4885
US-20120196866-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 FYN 1970/4885HPGD 172/4885GAA 138/4885
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES OPRD1, PPOX, CYP2D6 FYN 1868/4885HPGD 147/4885GAA 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.